Coronavirus: Pfizer vaccine shows long-term efficacy in adolescents
| Top stories | World News
Pfizer Inc said on Monday that its COVID-19 vaccine offered strong long-term protection against the virus in an advanced-stage study of adolescents aged 12 to 15.
A two-dose series of the vaccine was 100% effective against COVID-19, measured from seven days to more than four months after the second dose, the company said.
Long-term data will support planned submissions for full regulatory approval of the vaccine in the age group in the United States and globally.
Pfizer and BioNTech will seek approval for a 30 microgram dose of the vaccine for persons 12 years of age and older.
The vaccine was cleared for emergency use in people aged 12 to 15 by the United States Food & Drug Administration in May, and gained full approval for use in people aged 16 and over. more in August.
Report by Mrinalika Roy in Bengaluru; Editing by Shinjini Ganguli
News Today abc News Coronavirus: Pfizer vaccine shows long-term efficacy in adolescents